Clinical Trials Browser

Phase 2 × INDUSTRY × relacorilant × Clear all

NCT07259317 2026-02-20

Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

Phase 2 Recruiting

60 enrolled

Gastrointestinal

Adenocarcinoma, Carcinoma, Pancreatic Ductal

NCT03604198 2026-02-19

Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome

Phase 2 Active not recruiting

125 enrolled

Endocrine

ACTH Syndrome, Ectopic, Adrenal Cortex Neoplasms, Cushing Syndrome, Diabetes Mellitus, Type 2, Hypertension, Adrenocortical Carcinoma, Pituitary ACTH Hypersecretion

NCT06906341 2025-10-22

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

Phase 2 Recruiting

270 enrolled

Gynecologic

Fallopian Tube Diseases, Fallopian Tube Neoplasms, Genital Neoplasms, Female, Neoplasms, Neoplasms by Site, Ovarian Diseases, Ovarian Neoplasms, Peritoneal Neoplasms, Endometrial Neoplasms

NCT03776812 2025-10-07

Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2 Completed

178 enrolled 21 charts

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02804750 2019-10-15

Study to Evaluate CORT125134 in Participants With Cushing's Syndrome

Phase 2 Completed

35 enrolled 13 charts

Endocrine

ACTH Syndrome, Ectopic, Adrenal Cortex Neoplasms, Cushing Syndrome, Diabetes Mellitus, Type 2, Hypertension, Adrenocortical Carcinoma, Pituitary ACTH Hypersecretion